Citi is out with its report today on Johnson & Johnson JNJ, raising its PT from $71 to $73.
In a note to clients, Citi writes, "As expected, 2Q was not quite as robust as 1Q due to a generic hit in Pharma and a tougher environment in MD&D. JNJ still beat consensus EPS by $0.05 but it all came via a lower tax rate. JNJ is now just a quarter away from easier comparisons and accelerating organic sales growth. Based primarily on the lower tax rate, we are upping our 2011 and 2012 EPS each by $0.04, to $4.94 (+4%) and $5.19 (+5%). Our new target price is $73."
Citi maintains Buy on JNJ.
At the time of posting, shares of JNJ were trading pre-market at $67.12, up 0.60% from Tuesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in